Identify your patient’s actionable lung cancer mutations
Guideline-recommended, blood-based mutation results within 72 hours.
Nearly 80% of patients currently do not have mutation results available at their initial oncology consult.
How do we change this paradigm with blood-based testing?
Source: Lim, C., et.al. 2015. Biomarker Testing and Time to Treatment Decision in Patients with Advanced Non-Small Cell Lung Cancer. Ann Oncol first published online April 28, 2015
BLOOD-BASED RESULTS WITHIN 72 HOURS EXPEDITE TIME TO TREATMENT IN AS
LITTLE AS 8 DAYS2 FROM DIAGNOSTIC BIOPSY.
Tissue-based Tumor Mutation Testing: Presentation to Treatment
GeneStrat Tumor Mutation Testing: Presentation to Treatment
Reference: 1. NCCN Guidelines 2. Bowling, et al. J Clin Oncol 36, 2018 (suppl; abstr e18519) 3. Hagemann, et al. Cancer. 2015;121:631-9. 4. Vidaver RM et al. J Oncol Pract 2016 Jun 3;12(6):e643-53
Accurate, actionable genomic results
|Available Mutations||Clinical Sensitivity||Clinical Specificity||Concordance||Treatment Implications|
|EGFR Sensitizing del19, L858R||95.8%||100%||98.8%||May benefit from treatment with osimertinib, afatinib, erlotinib, gefitinib, or dacomitinib|
|EGFR Resistance T790M||86.7%||100%||96.4%||May benefit from osimertinib if previously treated with 1st or 2nd generation EGFR TKIs|
|EML4-ALK Fusions 1, 2, 3||85.0%||100%||92.0%||May benefit from treatment with alectinib, brigatinib, ceritinib, crizotinib, or lorlatinib, depending on previous therapies and other clinical factors|
|KRAS G12C, G12D, G12V||87.9%||100%||96.0%||KRAS mutations are associated with poorer prognosis|
|ROS1* CD74, SDC4, SLC34A2, EZR, TPM3||—||100%||—||May benefit from treatment with crizotinib, ceritinib, or lorlatinib, depending on previous therapies|
|RET* KIF5B, CCDC6, TRIM33||—||100%||—||May benefit from treatment with cabozantinib or vandetanib|
|BRAF* V600E||—||100%||—||May benefit from dabrafenib + trametinib, vemurafenib, or dabrafenib|
|GeneStrat Combined variant results||90.9%||100%||97.0%||See implications listed above for each variant|
*Clinical sensitivity and specificity were not calculated for ROS1, RET, and BRAF due to availability of samples with rare mutations (ROS1, RET) and treatment-naïve samples (BRAF) SEE DATA